CD47 and Decreased total leukocyte count: A primary challenge associated with CD47‐targeted therapies is the potential for hematologic toxicity, including anaemia, thrombocytopenia, and leukopenia, due to the widespread expression of CD47 on normal erythrocytes and platelets.